Candel Therapeutics (CADL) Total Current Liabilities (2020 - 2025)
Candel Therapeutics (CADL) posted Total Current Liabilities of $9.0 million for Q4 2025, down 17.68% sequentially from $10.9 million in Q3 2025, and down 76.03% YoY from $37.5 million in Q4 2024.
Candel Therapeutics (CADL) Total Current Liabilities (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Total Current Liabilities for 6 years, with the latest figure at $9.0 million in Q4 2025.
- Quarterly Total Current Liabilities fell 76.03% year-over-year to $9.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.0 million (down 76.03% YoY) and the FY2025 annual result came in at $9.0 million, down 76.03% from the prior year.
- Total Current Liabilities declined to $9.0 million in Q4 2025 per CADL's latest filing, from $10.9 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $37.5 million in Q4 2024 and troughed at $4.4 million in Q3 2021.
- A 5-year average of $11.1 million and a median of $9.0 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 164.59% in 2024, then slumped 76.03% in 2025.
- Over 5 years, Total Current Liabilities stood at $5.4 million in 2021, then rose by 4.72% to $5.6 million in 2022, then soared by 152.61% to $14.2 million in 2023, then jumped by 164.59% to $37.5 million in 2024, then plunged by 76.03% to $9.0 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $9.0 million, $10.9 million, and $14.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | 10.93 Mn |
| Jun 30, 2025 | 14.72 Mn |
| Mar 31, 2025 | 20.07 Mn |
| Dec 31, 2024 | 37.53 Mn |
| Sep 30, 2024 | 15.27 Mn |
| Jun 30, 2024 | 14.00 Mn |
| Mar 31, 2024 | 13.54 Mn |
| Dec 31, 2023 | 14.18 Mn |
| Sep 30, 2023 | 10.33 Mn |
| Jun 30, 2023 | 8.16 Mn |
| Mar 31, 2023 | 5.24 Mn |
| Dec 31, 2022 | 5.62 Mn |
| Sep 30, 2022 | 5.90 Mn |
| Jun 30, 2022 | 5.88 Mn |
| Mar 31, 2022 | 5.47 Mn |
| Dec 31, 2021 | 5.36 Mn |
| Sep 30, 2021 | 4.40 Mn |
| Jun 30, 2021 | 4.49 Mn |
| Dec 31, 2020 | 4.71 Mn |